{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:47:16Z","timestamp":1782733636137,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","award":["WBS4708719"],"award-info":[{"award-number":["WBS4708719"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Finnish Cultural Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007417","name":"Paulon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009067","name":"K Albin Johansson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"HUS Group","doi-asserted-by":"publisher","award":["TYH2020302"],"award-info":[{"award-number":["TYH2020302"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijgc.2025.101934","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T11:05:32Z","timestamp":1747479932000},"page":"101934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2976-2319","authenticated-orcid":false,"given":"Masuma","family":"Khatun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annukka","family":"Pasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Koivisto-Korander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taru","family":"Tuomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-2367","authenticated-orcid":false,"given":"Mikko","family":"Loukovaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clinicians"},{"issue":"7447","key":"10.1016\/j.ijgc.2025.101934_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2025.101934_bib3","series-title":"Female Genital Tumours","year":"2020"},{"key":"10.1016\/j.ijgc.2025.101934_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1146\/annurev-biochem-062917-012332","article-title":"Protein serine\/threonine phosphatases: keys to unlocking regulators and substrates","volume":"87","author":"Brautigan","year":"2018","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.onc.1207005","article-title":"Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage","volume":"23","author":"Dohoney","year":"2004","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0021-9258(17)49933-9","article-title":"Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers","volume":"295","author":"Farrington","year":"2020","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101934_bib7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/febs.13573","article-title":"All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase","volume":"283","author":"Sangodkar","year":"2016","journal-title":"FEBS Journal"},{"key":"10.1016\/j.ijgc.2025.101934_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3389\/fonc.2019.00462","article-title":"PP2A: a promising biomarker and therapeutic target in endometrial cancer","volume":"9","author":"Remmerie","year":"2019","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101934_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mc.20850","article-title":"PPP2R1A mutations are common in the serous type of endometrial cancer","volume":"51","author":"Nagendra","year":"2012","journal-title":"Mol Carcinog"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101934_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/path.2848","article-title":"Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas","volume":"223","author":"McConechy","year":"2011","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib11","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e29","article-title":"Genomic landscape of advanced endometrial cancer analyzed by targeted next-generation sequencing and the cancer genome atlas (TCGA) dataset","volume":"33","author":"Hong","year":"2022","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101934_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101934_bib13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2025.101934_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2025.101934_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"15","key":"10.1016\/j.ijgc.2025.101934_bib16","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101934_bib17","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/IGC.0000000000000801","article-title":"L1 cell adhesion molecule as a predictor of disease-specific survival and patterns of relapse in endometrial cancer","volume":"26","author":"Pasanen","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101934_bib18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438582","article-title":"Updates in the use of targeted therapies for gynecologic cancers","volume":"44","author":"Cantillo","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101934_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101934_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41379-020-0501-8","article-title":"Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma","volume":"33","author":"Pasanen","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101934_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101934_bib25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44276-025-00125-6","article-title":"HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups","volume":"3","author":"Aro","year":"2025","journal-title":"BJC Rep"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.ijgc.2025.101934_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbacli.2016.08.002","article-title":"The broken \u201cOff\u201d switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance","volume":"6","author":"Ruvolo","year":"2016","journal-title":"BBA Clin"},{"issue":"20","key":"10.1016\/j.ijgc.2025.101934_bib31","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101934_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.biocel.2018.01.005","article-title":"Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer","volume":"96","author":"Kauko","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101934_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-023-03193-1","article-title":"Altering phosphorylation in cancer through PP2A modifiers","volume":"24","author":"Johnson","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101934_bib34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/1535-7163.MCT-21-0880","article-title":"Small-molecule-mediated stabilization of PP2A modulates the homologous recombination pathway and potentiates DNA damage-induced cell death","volume":"22","author":"Avelar","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101934_bib35","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cell.2020.03.038","article-title":"Selective PP2A enhancement through biased heterotrimer stabilization","volume":"181","author":"Leonard","year":"2020","journal-title":"Cell"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:11:30Z","timestamp":1767996690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1048891X25010540"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101934","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: a cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101934"}}